Lifecore Expands Manufacturing Deal With Existing Pharma Client

Lifecore Biomedical, Inc. (NASDAQ: LFCR) has signed two CDMO manufacturing service agreements with an existing U.S. biopharmaceutical client. The first agreement involves a commercial site transfer for a currently marketed product, which Lifecore will manufacture after completing regulatory requirements. The second agreement expands Lifecore's services by allowing it to produce an ophthalmic treatment in a new delivery system, previously manufactured in Europe.